---
title: "Amylyx Pharmaceuticals, Inc. (AMLX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMLX.US.md"
symbol: "AMLX.US"
name: "Amylyx Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:11:54.635Z"
locales:
  - [en](https://longbridge.com/en/quote/AMLX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMLX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMLX.US.md)
---

# Amylyx Pharmaceuticals, Inc. (AMLX.US)

## Company Overview

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [amylyx.com](https://amylyx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.66)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 31.41% |  |
| P/B Ratio | 5.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1429856036.62 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -56.52% | E |
| Profit Margin | 22448.42% | A |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.34% | E |
| Net Profit YoY | 42.47% | B |
| Total Assets YoY | 44.68% | A |
| Net Assets YoY | 69.21% | A |
| Cash Flow Margin | 0.45% | C |
| OCF YoY | -100.34% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 8.48% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Amylyx Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "31.41%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1429856036.62",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-56.52%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "22448.42%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.34%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "42.47%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "44.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "69.21%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.34%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.48%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.44 | 184/190 | - | - | - |
| PB | 5.19 | 152/190 | 6.13 | 4.75 | 3.67 |
| PS (TTM) | -2526.68 | - | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 92% |
| Hold | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.74 |
| Highest Target | 34.00 |
| Lowest Target | 19.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AMLX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AMLX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AMLX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AMLX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**